Clonal Hematopoiesis of Indeterminate Potential (CHIP): A Model of Mutation-Driven Thromboinflammation.

Although CHIP carriers in the placebo arm exhibited only a nonsignificant trend toward increased major adverse cardiovascular events (MACE), patients harboring TET2-mutant CHIP derived substantial benefit from IL-1β inhibition with canakinumab [ 23 ].

also in 5,406 other papers